Skip to content
BIO 2025: A few highlights from Day 1
Day 1 of BIO 2025 was all about collaboration: how industry can collaborate with the U.S. government to advance biodefense, how collaboration is key […]
BIO 2025: A few highlights from Day 1 Read More »
BIO Events
Our reporters bring you news and highlights from BIO’s in-person and virtual events.
BIO 2025: A strong biodefense requires government-industry partnerships
Biotech’s contribution to America’s biodefense can only be supported through public-private partnerships, but the public sector must provide adequate support and private actors need
BIO 2025: A strong biodefense requires government-industry partnerships Read More »
BIO 2025: AI Summit highlights role of collaboration in reaching the next frontier
From drug discovery to clinical trials, AI is being used, studied, refined, and advanced as a means to slingshot biotech innovations into the future
BIO 2025: AI Summit highlights role of collaboration in reaching the next frontier Read More »
Welcome to BIO 2025: The world can’t wait.
The 2025 BIO International Convention, hosted by the Biotechnology Innovation Organization (BIO), opens June 16 in Boston, bringing together over 20,000 industry leaders from
Welcome to BIO 2025: The world can’t wait. Read More »
Gov. Healey, BIO Governor of the Year, boosts people to build biotech
To support and develop the world-leading biotech ecosystem of Massachusetts, Gov. Maura Healey puts a focus on people. Her work for biotech, which has
Gov. Healey, BIO Governor of the Year, boosts people to build biotech Read More »
BIO Coffee Chat: ORPHAN Cures Act key to fighting rare disease
America, for decades, has been the undisputed global leader when it comes to innovative drug development. But this leadership is now at risk. “We
BIO Coffee Chat: ORPHAN Cures Act key to fighting rare disease Read More »
BIO’s mission to Tokyo builds on fruitful cooperation
The BIO Delegation (pictured from left): Tasuku Kitada (Strand Therapeutics), Adam Roach (BeOne Medicines, formerly Beigene), Jacob Becraft (Strand Therapeutics), John F. Crowley (BIO),
BIO’s mission to Tokyo builds on fruitful cooperation Read More »
M&A comeback may face political headwinds, say BIO CEO panelists
When it comes to biotech M&A, 2024 wasn’t a great year, but it wasn’t “horrible,” according to analysts at the BIO CEO & Investor
M&A comeback may face political headwinds, say BIO CEO panelists Read More »
BIO coffee chat focuses on reimbursement for Accelerated Approval Pathway drugs
The U.S. Food and Drug Administration’s Accelerated Approval Pathway enables the timely development of treatments for severely ill patients who have few if any
BIO coffee chat focuses on reimbursement for Accelerated Approval Pathway drugs Read More »
BIO CEO 2025: Challenges and opportunities in the new administration
Seeking biotech-friendly policy from the new administration and Congress will be daunting and perhaps confusing, but there are still a lot of potential wins
BIO CEO 2025: Challenges and opportunities in the new administration Read More »